Severe hypophosphataemia after intravenous iron administration

Netherlands Journal of Medicine

Volumn 72, Issue 1, 2014, Pages 49-53

  Blazevic, A ^a   Hunze, J ^a   Boots, J M M ^a  

^a Maasstad Hospital Rotterdam   (Netherlands)

Author keywords

Adverse effects; Ferric compounds; Hypophosphaetemia; Intravenous iron administration supplementation

Indexed keywords

CALCIUM ION; COLECALCIFEROL; FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; FIBROBLAST GROWTH FACTOR 23; GLYCEROPHOSPHATE; GLYCOPHOS; HEMOGLOBIN; HYDROXOCOBALAMIN; IRON; IRON SACCHARATE; PHOSPHATE; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CYANOCOBALAMIN DEFICIENCY; DIETARY INTAKE; ENDOMETRIUM POLYP; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; MENORRHAGIA; MIDDLE AGED; VITAMIN D DEFICIENCY; WEAKNESS;

ADULT; ANEMIA, IRON-DEFICIENCY; ETHNIC GROUPS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPOPHOSPHATEMIA; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 84893020532     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55-62.
2. Afzal M, Qureshi SM, Lutafullah M, Iqbal M, Sultan M, Khan SA. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetae, iron polymatose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children. J Pak Med Assoc. 2009;59:764-8.
3. Krafft A, Perewusnyk G, Hänseler E, Quack K, Huch R, Breymann C. Effect of postpartum iron supplementation on red cell and iron parameters in non-anaemic iron-deficient women: a randomised placebo-controlled study. Int J Obstet Gynaecol. 2005;112:445-50.
4. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11:4.
5. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719-28.
6. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199:435. e1-7.
7. Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials. Anemia [Internet]. 2012 [cited 2013 Mar 3];2012. Available from: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3444829/
8. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysisdependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599-607.
9. Bergwitz C, Jüppner H. Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23. Ann Rev Med. 2010;61:91-104.
10. Haussler MR, Whitfield GK, Kaneko I, et al. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord. 2012;13:57-69.
11. Tiosano D. Fibroblast growth factor-23 and phosphorus metabolism. Endocr Dev. 2011;21:67-77.
12. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332-7.
13. Quarles LD. Role of FGF23 in Vitamin D and Phosphate Metabolism: Implications in Chronic Kidney Disease. Exp Cell Res. 2012 15;318:1040-8.
14. Evenepoel P, Meijers B, Viaene L, et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5:1268-76.
15. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003-8.
16. Lafage-Proust M-H. Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int. 2010;77:390-2.
17. Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010;77:232-8.
18. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis. 1992;19:303-17.
19. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-9.
20. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;n/a-n/a.
21. Farrow EG, Yu X, Summers LJ, Davis SI, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA. 2011 15;108:E1146-1155.
22. Felsenfeld AJ, Levine BS. Approach to Treatment of Hypophosphatemia. Am J Kidney Dis. 2012;60:655-61.
23. Riella LV, Rennke HG, Grafals M, Chandraker A. Hypophosphatemia in Kidney Transplant Recipients: Report of Acute Phosphate Nephropathy as a Complication of Therapy. Am J Kidney Dis. 2011;57:641-5.
24. Sato K, Nohtomi K, Demura H, et al. Saccharated ferric oxide (SFO)-induced osteomalacia: In vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone. 1997;21:57-64.
25. Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB. Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia. Anemia. 2013; doi: 10.1155/2013/169107.